Multiple sclerosis (MS) is a neurological disorder characterized by inflammatory demyelination and neurodegeneration in the central nervous system. Until recently, disease-modifying treatment was based on agents requiring parenteral delivery, thus limiting long-term compliance. Basic treatments such as beta-interferon provide only moderate efficacy, and although therapies for second-line treatment and highly active MS are more effective, they are associated with potentially severe side effects. Fingolimod (Gilenya®) is the first oral treatment of MS and has recently been approved as single disease-modifying therapy in highly active relapsing-remitting multiple sclerosis (RRMS) for adult patients with high disease activity despite basic treatment (beta-interferon) and for treatment-naïve patients with rapidly evolving severe RRMS. At a scientific meeting that took place in Vienna on November 18th, 2011, experts from ten Central and Eastern European countries discussed the clinical benefits and potential risks of fingolimod for MS, suggested how the new therapy fits within the current treatment algorithm and provided expert opinion for the selection and management of patients.
Метою даного дослідження було вивчення вірогідного впливу річного курсу компенсації дефіциту обміну 25(OH)D за допомогою офіцинального препарату вітаміну D на якість життя хворих із множинним склерозом. Проаналізовано дані спостереження за 57 пацієнтами з множинним склерозом. Через 1 рік у групі вітаміну D3 установлено значуще покращення оцінки загального сприйняття здоров’я (р = 0,002), життєздатності (р = 0,003), ролі емоційних проблем в обмеженні життєдіяльності (р = 0,01), показника психічного здоров’я (р = 0,008). Застосування вітаміну D3 позитивно позначилося на психічному компоненті якості життя.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.